Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

VIR earnings analysis

Filed May 6, 2026 · Our reading of the company's report

The latest report

Vir Biotechnology's Q1 2026 report reveals a significant downturn, reporting revenue of -$29,000 against expectations of $122.5 million, coupled with an EPS loss of $0.85, substantially below the estimated $0.38.…

Read full summary

Vir Biotechnology's Q1 2026 report reveals a significant downturn, reporting revenue of -$29,000 against expectations of $122.5 million, coupled with an EPS loss of $0.85, substantially below the estimated $0.38. Despite the disappointing results, the company maintains a robust cash position of $809.3 million, sufficient to fund operations into the latter half of 2028, and is actively progressing in clinical trials for its therapies targeting infectious diseases and cancer.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.85

What stood out

  • Significant Revenue Miss

    Reported revenue of -$29,000 against an estimate of $122.5 million.

  • Substantial EPS Loss

    Actual EPS of -0.85 far exceeded the estimated EPS of 0.38.

  • Strong Cash Position

    Cash, cash equivalents, and investments totaled $809.3 million as of March 31, 2026.

  • R&D Expense Decrease

    R&D expenses fell to $108.9 million from $118.6 million year-over-year.

  • Collaboration Agreement with Astellas

    Secured a $240 million upfront cash payment from Astellas for the collaboration on VIR-5500.

  • Liquidity Outlook Positive

    Company expects existing resources to fund operations through at least 2028.

What to watch

  • Increasing Net Loss

    Net loss widened to $125.7 million in Q1 2026 from a loss of $120.9 million in Q1 2025.

  • Regulatory Approval Challenges

    Future success substantially depends on timely clinical development, which may face unforeseen challenges.

  • Uncertain Revenue Stream

    Company does not expect significant revenue until regulatory approvals, with ongoing reliance on grants and collaborations.

Management's outlook

Outlook deferred to earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.